Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it ...

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Could the world’s best-selling drug have competition on the way? American pharmaceutical giant Bristol Myers Squibb agreed ...

Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...

The trial evaluated the combination of GSK’s Jemperli and Zejula as a first-line therapy for stage III and IV epithelial OC.

New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...

Almost one in five patients with advanced melanoma survived for five years after receiving lifileucel, with tumours shrinking ...

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad ...

Donaldson Company (NYSE: DCI) reported its Q3 FY25 results with sales rising 1.3% Y/Y to $940.1M, missing consensus. GAAP net ...

MERCK has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times (FT) reported on Monday, citing three people familiar with the matter. MoonLake's ...

Chinese doctors have reported a milestone in domestically made innovative medicine, announcing that a combination of ...